Safety and Immunogenicity Evaluation of the Recombinant Flagellin Protein Adjuvant
NCT06768697
·
clinicaltrials.gov ↗
EARLY_PHASE1
Phase
NOT_YET_RECRUITING
Status
60
Enrollment
OTHER_GOV
Sponsor class
Conditions
COVID - 19
Interventions
BIOLOGICAL:
KFD1(0µg )
BIOLOGICAL:
KFD1(20µg)
BIOLOGICAL:
KFD1(40µg)
BIOLOGICAL:
KFD1(80µg)
Sponsor
Shanghai Public Health Clinical Center